These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 11818201)
61. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Hunold A; Weddeling N; Paulussen M; Ranft A; Liebscher C; Jürgens H Pediatr Blood Cancer; 2006 Nov; 47(6):795-800. PubMed ID: 16411206 [TBL] [Abstract][Full Text] [Related]
62. Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. Fisher B; Won M; Macdonald D; Johnson DW; Roa W Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):980-6. PubMed ID: 12095566 [TBL] [Abstract][Full Text] [Related]
63. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer. Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862 [TBL] [Abstract][Full Text] [Related]
64. Phase I trial of simultaneous in-field boost with helical tomotherapy for patients with one to three brain metastases. Rodrigues G; Yartsev S; Yaremko B; Perera F; Dar AR; Hammond A; Lock M; Yu E; Ash R; Caudrelier JM; Khuntia D; Bailey L; Bauman G Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1128-33. PubMed ID: 20675078 [TBL] [Abstract][Full Text] [Related]
65. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. Rose PG; Smrekar M; Haba P; Visser C; Beeler JF Gynecol Oncol; 2005 Dec; 99(3):714-9. PubMed ID: 16112177 [TBL] [Abstract][Full Text] [Related]
66. Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer. Acevedo-Gadea C; Santin AD; Higgins SA; Urva S; Ratner E; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Abu-Khalaf MM Int J Gynecol Cancer; 2014 Mar; 24(3):528-33. PubMed ID: 24557436 [TBL] [Abstract][Full Text] [Related]
67. A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum. Brown JV; Rettenmaier MA; Lopez KL; Graham C; Micha JP; Goldstein B Int J Gynecol Cancer; 2008; 18(2):249-54. PubMed ID: 18334007 [TBL] [Abstract][Full Text] [Related]
68. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Ramasubbaiah R; Perkins SM; Schilder J; Whalen C; Johnson CS; Callahan M; Jones T; Sutton G; Matei D Gynecol Oncol; 2011 Dec; 123(3):499-504. PubMed ID: 21955480 [TBL] [Abstract][Full Text] [Related]
69. ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study. Gwak HS; Youn SM; Kwon AH; Lee SH; Kim JH; Rhee CH J Neurooncol; 2005 Nov; 75(2):173-80. PubMed ID: 16132508 [TBL] [Abstract][Full Text] [Related]
70. Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma. Puls LE; Hunter JE; Crane MM Med Oncol; 2002; 19(1):25-33. PubMed ID: 12025888 [TBL] [Abstract][Full Text] [Related]
71. The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience. Hu CF; Ou YC; Fu HC; Chang Chien CC; Tsai CC; Wu CH; Lin H Taiwan J Obstet Gynecol; 2015 Feb; 54(1):43-7. PubMed ID: 25675918 [TBL] [Abstract][Full Text] [Related]
72. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125 [TBL] [Abstract][Full Text] [Related]
73. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial. Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475 [TBL] [Abstract][Full Text] [Related]
74. Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system. Kushner BH; Kramer K; Modak S; Kernan NA; Reich LM; Danis K; Cheung NK Bone Marrow Transplant; 2006 Feb; 37(3):271-6. PubMed ID: 16400336 [TBL] [Abstract][Full Text] [Related]
75. Topotecan as a 21-day continuous infusion with accelerated 3D-conformal radiation therapy for patients with glioblastoma. Grabenbauer GG; Buchfelder M; Schrell U; Fahlbusch R; Sauer R; Staab HJ Front Radiat Ther Oncol; 1999; 33():364-8. PubMed ID: 10549508 [No Abstract] [Full Text] [Related]
76. Experience with independent radiological review during a topotecan trial in ovarian cancer. Gwyther S; Bolis G; Gore M; ten Bokkel Huinink W; Verweij J; Hudson IR; Despax R; Jiménez-Lacave A Ann Oncol; 1997 May; 8(5):463-8. PubMed ID: 9233526 [TBL] [Abstract][Full Text] [Related]
77. Systemic Treatment for Brain Metastasis and Leptomeningeal Disease in Breast Cancer Patients. Puri S; Chaudhry A; Bayable A; Ganesh A; Daher A; Gadi VK; Maraka S Curr Oncol Rep; 2023 Dec; 25(12):1419-1430. PubMed ID: 37924439 [TBL] [Abstract][Full Text] [Related]
78. A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Neuhaus T; Ko Y; Muller RP; Grabenbauer GG; Hedde JP; Schueller H; Kocher M; Stier S; Fietkau R Br J Cancer; 2009 Jan; 100(2):291-7. PubMed ID: 19127261 [TBL] [Abstract][Full Text] [Related]
79. Predictors for patterns of brain relapse and overall survival in patients with non-small cell lung cancer. Tang SG; Tseng CK; Tsay PK; Chen CH; Chang JW; Pai PC; Hong JH J Neurooncol; 2005 Jun; 73(2):153-61. PubMed ID: 15981106 [TBL] [Abstract][Full Text] [Related]
80. Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases. Grüschow K; Klautke G; Fietkau R Eur J Cancer; 2002 Feb; 38(3):367-74. PubMed ID: 11818201 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]